Frontage Laboratories Inc., (HKG: 1521), a Contract Research Organization (CRO) with operations in Pennsylvania, Suzhou, and Shanghai, has announced the completion of its acquisition of the Bioanalytical and Drug Metabolism & Pharmacokinetics (DMPK) businesses from Italy-based CRO Accelera S.r.l. The specifics of the deal were not disclosed.
This acquisition is considered a significant milestone for Frontage, as it establishes a presence for the company in continental Europe. The company aims to continue serving Accelera’s existing DMPK clients in addition to its own customer base. As Accelera is part of Italy’s Nerviano Medical Sciences Group S.p.A. (NMS), Frontage anticipates closer collaboration with NMS in providing drug discovery and development process services.- Flcube.com
